Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes

医学 前列腺癌 随机对照试验 内科学 肿瘤科 放射治疗 临床试验 癌症 危险系数 置信区间
作者
Safae Terrisse,Eleni Karamouza,Chris Parker,A. Oliver Sartor,Nicholas D. James,Sarah Pirrie,Laurence Collette,Bertrand Tombal,Jad Chahoud,Sigbjørn Smeland,Bjørn Erikstein,Jean‐Pierre Pignon,Karim Fizazi,Gwénaël Le Teuff
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:6 (2): 206-206 被引量:21
标识
DOI:10.1001/jamaoncol.2019.4097
摘要

Importance

Both α-emitting and β-emitting bone-targeted radioisotopes (RIs) have been developed to treat men with metastatic castration-resistant prostate cancer (CRPC). Only 1 phase 3 randomized clinical trial has demonstrated an overall survival (OS) benefit from an α-emitting RI, radium 223 (223Ra), vs standard of care. Yet no head-to-head comparison has been done between α-emitting and β-emitting RIs.

Objective

To assess OS in men with bone metastases from CRPC treated with bone-targeted RIs and to compare the effects of α-emitting RIs with β-emitting RIs.

Data Sources

PubMed, Cochrane Library, ClinicalTrials.gov, and meeting proceedings between January 1993 and June 2013 were reviewed. Key terms includedrandomized trials,radioisotopes,radiopharmaceuticals, andprostate cancer. Data were collected, checked, and analyzed from February 2017 to October 2018.

Study Selection

Selected trials included patients with prostate cancer, recruited more than 50 patients from January 1993 to June 2013, compared RI use with no RI use (placebo, external radiotherapy, or chemotherapy), and were randomized. Patients were diagnosed with histologically proven prostate cancer and disease progression after both surgical or chemical castration and have evidence of bone metastasis. Nine randomized clinical trials were identified as eligible, but 3 were excluded for insufficient data.

Data Extraction and Synthesis

Individual patient data were requested for each eligible trial, and all data were checked with a standard procedure. The log-rank test stratified by trial was used to estimate hazard ratios (HRs), and a similar fixed-effects (FE) model was used to estimate odds ratios (ORs). The between-trial heterogeneity of treatment effects was evaluated by Cochran test andI2and was accounted by a random-effects (RE) model.

Main Outcomes and Measures

Overall survival; secondary outcomes were symptomatic skeletal event (SSE)–free survival and adverse events.

Results

Based on 6 randomized clinical trials including 2081 patients, RI use was significantly associated with OS compared with no RI use (HR, 0.86; 95% CI, 0.77-0.95;P = .004) with high heterogeneity (χ25 = 24.46;P < .001;I2 = 80%), but this association disappeared when using an RE model (HR, 0.80; 95% CI, 0.61-1.06;P = .12; τ2 = 0.08). The heterogeneity is explained both by the type of RI and by the inclusion of 2 outlier trials that included 275 patients; the OS benefit was significantly higher with the α-emitting RI223Ra (HR, 0.70; 95% CI, 0.58-0.83) but not significant with the β-emitting RI strontium-89 (HR, 0.96; 95% CI, 0.84-1.10) (Pfor interaction = .004). Excluding the outlier trials led to an overall HR of 0.82 (95% CI, 0.73-0.92;P < .001) (between-trial heterogeneity: χ23 = 6.51;P = .09;I2 = 54%) using an FE model and an HR of 0.80 (95% CI, 0.65-0.99;P = .04; τ2 = 0.02) using an RE model. The HR for SSE-free survival was 0.81 (95% CI, 0.69-0.93;P = .004) (between-trial heterogeneity: χ23 = 6.71;P = .08;I2 = 55%) when using an FE model and was 0.76 (95% CI, 0.58-1.01;P = .06; τ2 = 0.04) when using an RE model. There were more hematological toxic effects with RI use compared with no RI use (OR, 1.48; 95% CI, 1.17-1.88;P = .001).

Conclusions and Relevance

In metastatic CRPC, a significant improvement of OS and SSE-free survival was obtained with bone-targeted α-emitting but not β-emitting RIs. Caution is necessary for generalizability of these results, given the between-trial heterogeneity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
huohuo完成签到,获得积分10
1秒前
CB完成签到,获得积分10
2秒前
2秒前
3秒前
儒雅路人完成签到,获得积分10
4秒前
OLDBLOW完成签到,获得积分10
5秒前
5秒前
liupangzi完成签到,获得积分10
5秒前
wang完成签到,获得积分10
5秒前
6秒前
Catherkk发布了新的文献求助10
6秒前
lcdamoy完成签到,获得积分10
7秒前
钱浩然发布了新的文献求助10
7秒前
烊烊发布了新的文献求助10
8秒前
十曰完成签到,获得积分10
13秒前
jjjjchou完成签到,获得积分10
14秒前
虚心的不二完成签到 ,获得积分10
16秒前
xuzj应助科研通管家采纳,获得10
17秒前
小马甲应助科研通管家采纳,获得10
17秒前
17秒前
思源应助科研通管家采纳,获得10
17秒前
17秒前
研友_VZG7GZ应助科研通管家采纳,获得10
17秒前
fang应助科研通管家采纳,获得10
17秒前
隐形曼青应助科研通管家采纳,获得10
17秒前
科研通AI5应助科研通管家采纳,获得10
17秒前
FashionBoy应助科研通管家采纳,获得10
17秒前
shiizii应助科研通管家采纳,获得10
17秒前
19秒前
火星上的雨莲完成签到,获得积分10
23秒前
开朗的绮山发布了新的文献求助150
23秒前
平淡远山发布了新的文献求助10
24秒前
热心市民小红花应助Roman采纳,获得10
25秒前
艺术家完成签到 ,获得积分10
26秒前
研友_ngqjz8完成签到,获得积分10
27秒前
LT完成签到 ,获得积分0
28秒前
优秀的dd完成签到 ,获得积分10
29秒前
JamesPei应助八月宁静采纳,获得10
29秒前
www完成签到 ,获得积分10
31秒前
自由如天完成签到,获得积分10
31秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022